Who Generates Higher Gross Profit? AbbVie Inc. or Pfizer Inc.

A Decade of Gross Profit: AbbVie Inc. vs. Pfizer Inc.

In the ever-evolving pharmaceutical industry, the battle for market dominance is often reflected in financial performance. Over the past decade, from 2014 to 2023, AbbVie Inc. and Pfizer Inc. have been at the forefront, showcasing their prowess through gross profit generation.

Key Insights

Pfizer Inc. consistently outperformed AbbVie Inc. in gross profit, with Pfizer's peak in 2022 reaching approximately 66 billion, a staggering 62% higher than AbbVie's peak in the same year. However, AbbVie demonstrated remarkable growth, with its gross profit increasing by 118% from 2014 to 2022.

The Turning Point

Interestingly, 2023 marked a shift, with AbbVie surpassing Pfizer, generating around 34 billion compared to Pfizer's 29 billion. This change highlights the dynamic nature of the industry and the strategic maneuvers companies must make to stay ahead.